Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: Rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1

Human Molecular Genetics

Volumn 17, Issue 19, 2008, Pages 2934-2948

  Rosner, Margit ^a   Hengstschläger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RAPAMYCIN INSENSITIVE COMPANION OF MTOR; REGULATOR PROTEIN; REGULATORY ASSOCIATED PROTEIN OF MTOR; STRESS ACTIVATED PROTEIN KINASE INTERACTING PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL COMPARTMENTALIZATION; CELL CYCLE ARREST; CELL NUCLEUS; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; DIABETES MELLITUS; DIPLOIDY; FIBROBLAST; HEART HYPERTROPHY; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; KIDNEY POLYCYSTIC DISEASE; MOLECULAR DYNAMICS; NEOPLASM; NEUROFIBROMATOSIS; OBESITY; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REGULATORY MECHANISM; SHORT COURSE THERAPY; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARRIER PROTEINS; CELL CYCLE; CELL NUCLEUS; CELLS, CULTURED; CYTOPLASM; FIBROBLASTS; HUMANS; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN TRANSPORT; SIROLIMUS; TRANSCRIPTION FACTORS;

MAMMALIA; RAPTORES;

EID: 52949137425     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn192     Document Type: Article

References (75)

1. Guertin, D.A. and Sabatini, D.M. (2007) Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
2. Yang, Q. and Guan, L. (2007) Expanding mTOR signalling. Cell Res., 17, 666-681.
3. Chiang, G.G. and Abraham, R.T. (2007) Targeting the mTOR signalling network in cancer. Trends Mol. Med., 13, 433-442.
4. Dann, S.G., Selvaraj, A. and. Thomas, G. (2007) mTOR complex 1-S6K1 signaling: At the crossroads of obesity, diabetes and cancer. Trends Mol. Med., 13, 252-259.
5. Bhaskar, P.T. and Hay, N. (2007) The two TORCs and Akt. Dev. Cell, 12, 487-502.
6. Manning, B.D. and Cantley, L.C. (2007) AKT/PKB signalling: Navigating downstream. Cell, 129, 1261-1274.
7. Wullschleger, S., Loewith, R. and Hall, M. (2006) TOR signaling in growth and metabolism. Cell, 124, 471-484.
8. Bai, X., Ma, D., Liu, A., Shen, X., Wang, Q.J., Liu, Y. and Jiang, Y. (2007) Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science, 318, 977-980.
9. Crino, P.B., Nathanson, K.L. and Henske, E.P. (2006) The tuberous sclerosis complex. N. Engl. J. Med., 355, 1345-1356.
10. Yang, Q., Inoki, K., Kim, E. and Guan, L. (2006) TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc. Natl Acad. Sci. USA, 103, 6811-6816.
11. Huang, J., Dibble, C.C., Matsuzaki, M. and Manning, B.D. (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol., doi:10.1128/MCB.00289-08.
12. Corradetti, M.M., Inoki, K., Bardeesy, N., DePinho, R.A. and Guan, L. (2004) Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev., 18, 1533-1538.
13. Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kostmatka, M., DePinho, R.A. and Cantley, C. (2004) The LKB1 tumor suppressor negatively regulates mTOR signalling. Cancer Cell, 6, 91-99.
14. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennet, C., Harada, Y., Stankunas, K. et al. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 126, 955-968.
15. Brugarolas, J. and Kaelin, W.G. (2004) Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6, 7-10.
16. Inoki, K., Corradetti, M.N. and Guan, L. (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nature Genet., 37, 19-24.
17. Brugarolas, J., Vazquez, F., Reddy, A., Sellers, W.R. and Kaelin, W.G. (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell, 4, 147-156.
18. El-Hashemite, N., Walker, V., Zhang, H. and Kwiatkowski, D.J. (2003) Loss of Tsc1 and Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res., 63, 5173-5177.
19. Johannessen, C., Reczek, E.E., James, M.F., Brems, H., Legius, E. and Cichowski, K. (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA, 102, 8573-8578.
20. Johannessen, C., Johnson, B.W., Williams, S.M.G., Chan, A.W., Reczek, E.E., Lynch, R.C., Rioth, M.J., McClathehey, A., Ryeom, S. and Cichowski, K. (2008) TORC1 is essential for NF1-associated malignancies. Curr. Biol., 18, 56-62.
21. Kleymenova, E., Ibraghimov-Beskrovnaya, O., Kugoh, H., Everitt, J., Xu, H., Kiguchi, K., Landes, G., Harris, P. and Walker, C.L. (2001) Tuberin-dependent membrane localization of polycystin-1: A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol. Cell, 7, 823-832.
22. Shillingford, J.M., Murcia, N.S., Larson, C.H., Low, S.H., Hedgepeth, R., Brown, N., Flask, C.A., Novick, A.C., Goldfarb, D.A., Kramer-Zucker, A. et al. (2006) The mTOR pathway is regulated by polycystin-1 and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci., 103, 5466-5471.
23. Lee, D.F., Kuo, H.-P., Chen, C.-T., Hsu, J.-M., Chou, C.-K., Wie, Y., Sun, H.-L., Li, L.-Y., Ping, B., Huang, W.-C. et al. (2007) IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell, 130, 440-455.
24. An, W.L., Cowburn, R.F., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.G., Winblad, B. and Pei, J.J. (2003) Up-regulation of phosphorylated/ activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol., 163, 591-607.
25. Li, X., Alafuzoff, I., Soininen, H., Winblad, B. and Pei, J.J. (2005) Levels of mTOR and its downstream targets 4E-BP1, eEF2 and eEF2 kinase in relationships with tau in Alzheimeŕs disease brain. FEBS J., 272, 4211-4220.
26. Griffin, R.J., Moloney, A., Kelliher, M., Johnston, J.A., Ravid, R., Dockery, P., ÒConnor, R. and ÒNeill, C. (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimeŕs disease pathology. J. Neurochem., 93, 105-117.
27. Ferrando-Miguel, R., Rosner, M., Freilinger, A., Lubec, G. and Hengstschläger, M. (2005) Tuberin - a new molecular target in Alzheimeŕs disease? Neurochem. Res., 30, 1413-1419.
28. Chano, T., Okabe, H. and Hulette, C.M. (2007) RB1CC1 insufficiency causes neuronal atrophy through mTOR signalling alteration and is involved in the pathology of Alzheimeŕs diasease. Brain Res., 1168, 97-105.
29. Damjanac, M., Rioux Bilan, A., Paccalin, A., Pontcharraud, R., Fauconneau, B., Hugon, J. and Page, G. (2008) Dissociation of Akt/PKB and ribosomal S6 kinase signalling markers in a transgenic mouse model of Alzheimeŕs disease. Neurobiol. Dis., 29, 354-367.
30. Blair, E., Redwood, C., Ashrafian, H., Oliveira, M., Broxholme, J., Ker, B., Salmon, A., Ostman-Smith, I. and Watkins, H. (2001) Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet., 10, 1215-1220.
31. Shioi, T., McMullen, J.R., Tamavski, O., Converso, K., Sherwood, M.C., Manning, W.J. and Izumo, S. (2003) Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation, 107, 1664-1670.
32. Chan, A.Y., Soltys, C.L., Young, M.E., Proud, C.G. and Dyck, J.R. (2004) Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 279, 32771-32779.
33. Zick, Y. (2005) Ser/thr phosphorylation of IRS proteins: A molecular basis for insulin resistance. Sci. STKE, 25, e4.
34. Knowles, M.A., Homigold, N. and Pitt, E. (2003) Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem. Soc. Trans., 31, 597-602.
35. Pymar, L.S., Platt, F.M., Askham, J.M., Morrison, E.E. and Knowles, M.A. (2008) Bladder tumor derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum. Mol. Genet., April 7, Epub ahead of print.
36. Kataoka, K., Fujimoto, K., Ito, D., Koizumi, M., Toyoda, E., Mori, T., Kami, K. and Doi, R. (2005) Expression and prognostic Value of tuberous sclerosis complex 2 gene product in human pancreatic cancer. Surgery 138, 450-455.
37. Jiang, W.G., Sampson, J., Martin, T.A., Lee-Jones, L., Watkins, G., Douglas-Jones, A., Mokbel, K. and Mansel, R.E. (2005) Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: The role of promoter methylation of TSC genes. Euro. J. Cancer, 41, 1628-1636.
38. Lu, K.H., Wu, W., Dave, B., Slomovitz, B.M., Burke, T.W., Munsell, M.F., Broaddus, R.R. and Walker, C.L. (2008) Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signalling in endometrial cancer. Clin. Cancer Res., 14, 2543-2550.
39. Soucek, T., Yeung, R.S. and Hengstschläger, M. (1998) Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl Acad. Sci. USA, 95, 15653-15658.
40. Miloloza, A., Rosner, M., Nellist, M., Halley, D., Bemaschek, G. and Hengstschläger, M. (2000) The TSC1 gene product, hamartin, negatively regulates cell proliferation. Hum. Mol. Genet., 9, 1721-1727.
41. Rosner, M. and Hengstschläger, M. (2004) Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J. Biol. Chem., 279, 48707-48715.
42. KIP1 localization depends on the tumor suppressor protein tuberin. Hum. Mol. Genet., 16, 1541-1556.
43. Brugarolas, J. (2007) Renal-cell carcinoma - molecular pathway and therapies. N. Engl. J. Med., 356, 185-187.
44. Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J-H., Hsu, P.P., Bagley, A.F., Markhard, A.L. and Sabatini, D.M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168.
45. Neri, L.M., Borgatti, P., Capitani, S. and Martelli, A.M. (2002) The nuclear phosphoinositide 3-kinase/AKT pathway: A new second messenger system. Biochim. Biophys. Acta, 1584, 73-80.
46. Kikani, C.K., Dong, L.Q. and Liu, F. (2005) 'New'-clear functions of PDK1: Beyond a master kinase in the cytosol? J. Cell. Biochem., 96, 1157-1162.
47. Pekarsky, Y., Koval, A., Hallas, C., Bichi, R., Tresini, M., Malstrom, S., Russo, G., Tsichlis, P. and Croce, C.M. (1999) Tc11 enhances Akt kinase activity and mediates its nuclear translocation. Proc. Natl Acad Sci. USA, 97, 3028-3033.
48. Borgatti, P., Martelli, A.M., Bellacosa, M., Casto, R., Massari, L., Capitani, S. and Neri, L.M. (2000) Translocation of Akt/PKB to the nucleus of osteoblast-like MC3T3-E1 cells exposed to proliferative growth factors. FEBS Lett., 477, 27-32.
49. Tsujita, Y., Muraski, J., Shiraishi, I., Kato, T., Kajstura, J., Anversa, P. and Sussman, M.A. (2006) Nuclear targeting of Akt antagonizes aspects of cardiomoycte hypertrophy. Proc. Natl Acad. Sci. USA, 103, 11946-11951.
50. Ahn, J-Y., Liu, X., Lju, Z., Pereira, L., Cheng, D., Peng, J., Wade, P.A., Hamburger, A.W. and Ye, K. (2006) Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J., 25, 2083-2095.
51. Wang, R. and Brattain, M.G. (2006) AKT can be activated in the nucleus. Cell. Signal., 18, 1722-1731.
52. Trotman, L.C., Alimonti, A., Scaglioni, P.P., Koutcher, J.A., Cordon-Cardo, C. and Pandolfi, P.P. (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 441 523-527.
53. Lian, Z. and Di Christofano, A. (2005) Class reunion: PTEN joins the nuclear crew. Oncogene, 24, 7394-7400.
54. Trotman, L.C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N.P., Carver, B.S., Cordon-Cardo, C., Erdjument-Bromage, H. et al. (2007) Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell, 128, 141-156.
55. Wienecke, R., Maize, J.C., Shoarinejad, F., Vass, W.C., Reed, J., Bonifacino, J.S., Resau, J.H., de Gunzburg, J., Yeung, R.S. and DeClue, J.E. (1996) Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus. Oncogene, 13, 913-923.
56. Nellist, M., van Slegtenhorst, M.A., Goedbloed, M., van den Ouweland, A.M., Halley; D.J. and Van der Sluijs, P. (1999) Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J. Biol. Chem., 274, 35647-35652.
57. Lou, D., Griffith, N. and Noonan, D.J. (2001) The tuberous sclerosis 2 gene product can localize to nuclei in a phosphorylation-dependent manner. Mol. Cell. Biol. Res. Commun., 4, 374-380.
58. Rosner, M., Freilinger, A. and Hengstschigger, M. (2007) Akt regulates nuclear/cytoplasmic localization of tuberin. Oncogene, 26, 521-531.
59. Kim, S-J. and Kahn, C.R. (1997) Insulin stimulates p70SKinase in the nucleus of cells. Biochem. Biophys. Res. Comm., 234, 681-685.
60. Ruvinsky, I. and Meyuhas, O. (2006) Ribosomal protein S6 phosphorylation: From protein synthesis to cell size. Trends Biochem. Sci., 31, 342-446.
61. Krüger, Y., Zentgraf, H. and Scheer, U. (2007) Intranucleolar sites of ribosome biogenesis defined by the localization of early binding ribosomal proteins. J. Cell Biol., 177, 573-578.
62. Kim, J.E. and Chen, J. (2000) Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc. Natl Acad. Sci. USA, 97, 14340-14345.
63. Zhang, X., Shu, L., Hosoi, H., Murit, K.G. and Houghton, P.J. (2002) Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J. Biol. Chem., 277, 28127-28134.
64. Bachmann, R.A., Kim, J-H., Wu, A-L., Park, I-H. and Chen, J. (2006) A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 Kinase 1. J. Biol. Chem., 281, 7357-7363.
65. Furuya, F., Hanover, J.A. and Cheng, Y. (2006) Activation of phosphatidylinositol 3-kinase signalling by a mutant thyroid hormone receptor. Proc. Natl Acad Sci USA, 103, 1780-1785.
66. Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Fitzgerald, K.J. and Sabatini, D.M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 11, 859-871.
67. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J. and Su, B. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell, 126, 1-13.
68. Frias, M.A., Thoreen, C.C., Jaffe, J.D., Schroder, W., Sculley, T., Carr, S.A. and Sabatini, D.M. (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol., 16, 1865-1870.
69. Yang, Q., Inoki, K., Ikenoue, T. and Guan, L. (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev., 20, 2820-2832.
70. Akcakanat, A., Singh, G., Hung, M-C. and Meric-Bernstam, F. (2007) Rapamycin regulates the phosphorylation of rictor. Biochem. Biophys. Res. Comm, 362, 330-333.
71. Bissler, J.J., McCormack, F.X., Young, L.R., Owing, J.M., Chuck, G., Leonard, J.M., Schmithorst, V.J., Laor, T., Brody, A.S., Bean, J., Salisbury, S. and Fran, D.N. (2008) Sirolimus for angimyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New Engl. J. Med, 358, 140-151.
72. Davies, D.M., Johnson, S.R., Tattersfield, A.E., Kingswood, J.C., Cox, J.A., McCartney, D.L., Doyle, T., Elmslie, F., Saggar, A., DeVries, P.J. and Sampson, J.R. (2008) Sirolimus theraoy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med, 358, 200-203.
73. Paul, E. and Thiele, E. (2008) Efficacy of Sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N Engl. J. Med, 358, 190-192.
74. Sarbassov, D.D. and Sabatini, D.M. (2005) Redox Regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J. Biol. Chem. 280, 39505-39509.
75. Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya-Feldstein, J., Cordon-Cardo, C., Simon, M.C., Rafii, S. and Pandolfi, P.P. (2006) PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature, 442, 779-785.